Professionals worry that the findings have overshadowed the long-term benefits of school- and family-based skills programs. The original findings also gave pharmaceutical companies a significant marketing tool – now more than two-thirds of American children with ADHD take medication for the condition. And insurers have also used the study to deny coverage of psychosocial therapy, which costs more than daily medication but may deliver longer-lasting benefits, according to the Times. According to the news report, an insured family might pay $200 a year for stimulants, while individual or family therapy can be time-consuming and expensive, reaching $1,000 or more.
“I hope it didn’t do irreparable damage,” study coauthor Lily Hechtman, MD, of McGill University in Montreal, told the Times. “The people who pay the price in the end [are] the kids. That’s the biggest tragedy in all of this.”
Now they tell us.